Abstract The prognosis of HER2-positive breast cancer has been improved by trastuzumab therapy, which features high specificity and limited side effects. However, trastuzumab-based therapy has shortcomings. Firstly, HER2-targeted therapy is only applicable to HER2-expressing tumors, which comprise only 20-25 % of primary breast cancers. Secondly, many patients who initially respond to trastuzumab ultimately develop disease progression. To overcome these problems, we employed virus-mediated HER2 transduction and photoimmunotherapy (PIT) which involves trastuzumab conjugated with a photosensitizer, trastuzumab-IR700, and irradiation of near-infrared light. We hypothesized that the gene transduction technique together with PIT would expand the range of tumor entities suitable for trastuzumab-based therapy and improve its antitumor activity. The HER2-extracellular domain (ECD) was transduced by the adenoviral vector, Ad-HER2-ECD, and PIT with trastuzumab-IR700 was applied in the HER2-negative cancer cells. Ad-HER2-ECD can efficiently transduce HER2-ECD into HER2-negative human cancer cells. PIT with trastuzumab-IR700 induced direct cell membrane destruction of Ad-HER2-ECD-transduced HER2-negative cancer cells. Novel combination of viral transduction of a target antigen and an antibody-based PIT would expand and potentiate molecular-targeted therapy even for target-negative or attenuated cancer cells.
XTT
The sodium 3 0 -[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro) benzene sulfonic acid hydrate Introduction HER2 is a well-known oncogene, the overexpression of which is strongly associated with more aggressive tumors and poorer overall survival [1] . Strategies such as trastuzumab that target HER2 have greatly improved the prognosis of HER2-positive breast cancer through their high specific targeting ability [2] . However, the clinical efficacy of HER2-targeted therapy is limited to breast cancers that overexpress HER2, which only account for 20-30 % of all breast cancer [3, 4] and which are also inclined to develop resistance [5] . In addition, although trastuzumab is known to have few side effects apart from cardiac toxicity, trastuzumab is usually used together with an anti-tumor drug [6, 7] , because its effect is not strong enough when used as a sole agent.
Photoimmunotherapy (PIT) was developed as a new type of molecular-targeted cancer therapy. PIT uses specific monoclonal antibodies that are targeted toward cell surface receptors and that are conjugated to the photosensitizer phthalocyanine dye, IR700, which is cytotoxic upon irradiation with near-infrared (NIR) light [8] . Trastuzumab-IR700 (Tra-IR700) was designed to specifically target HER2-expressing cells. Cell death is only induced when the cells are bound by Tra-IR700 and irradiated with NIR light. Death is presumably induced by cell membrane damage due to local expansion of heated water [8] .
Modified adenovirus type 5 vectors have been widely used as a platform for the delivery of genes of interest into various types of human cells. In a previous study, we constructed a replication-deficient adenoviral vector containing a gene that encodes the HER2 extracellular domain (Ad-HER2-ECD) [9] . We demonstrated that infection with Ad-HER2-ECD resulted in expression of the HER2-ECD on the surface of HER2-negative or trastuzumab-resistant HER2-attenuated cancer cells. The expressed HER2-ECD did not trigger HER2 signaling pathways because of the lack of the HER2 intracellular kinase domain [9] .
We hypothesized that if the Ad-HER2-ECD-mediated gene transduction technique was used together with molecular-targeted cancer therapy using PIT, the range of tumor entities suitable for trastuzumab-based therapy would be expanded and the problem of resistance and narrow indication could be overcome.
Materials and methods

Cell lines and cell cultures
Three human mammary gland adenocarcinoma cell lines, SKBR3, MDA-MB-231, and MCF7, were obtained from the American Type Culture Collection. SKBR3, MDA-MB-231, and MCF7 were cultured in McCoy's 5A medium, Leibovitz's L-15 Medium, and Dulbecco's modified Eagle's medium (DMEM) supplemented with 2 mmol/ml L-glutamine, respectively. The human osteosarcoma cell line Saos-2 was kindly provided by Dr. Kyo (Kanazawa University, Ishikawa, Japan), and the cells were propagated as monolayer cultures in DMEM. Penicillin (100 units/ml), streptomycin (100 lg/ml), and 10 % fetal bovine serum were added to the medium. The cells were maintained at 37°C in a humidified atmosphere with 5 % CO 2 .
Recombinant adenovirus
A replication-deficient adenoviral vector expressing the extracellular and trans-membrane domains of HER2 (Ad-HER2-ECD) was constructed [9] . Briefly, the HER2-ECD expression cassette, which contains the human cytomegalovirus promoter, HER2-ECD cDNA, and the SV40 early polyadenylation signal, was inserted between the XbaI and ClaI sites of pXCJL.1. The HER2-ECD shuttle vector and the recombinant plasmid pJM17 were cotransfected into 293 cells. The culture supernatant of 293 cells that showed the complete cytopathic effect, which contained virus progenies, was collected and used for subsequent production. The resultant virus was purified by ultracentrifugation in cesium chloride step gradients, and its titer was determined by a plaque-forming assay using 293 cells. The virus was stored at -80°C until use. Ad-GFP was used as a control adenovirus [10] .
Western blotting analysis
Primary antibodies against HER2-ECD (Ab-20, Thermo Scientific) and b-actin (AC-15, Sigma Chemical, Co.) were used. Proteins were electrophoretically transferred to Hybond-polyvinylidene difluoride transfer membranes (GE Healthcare Life Science), incubated with primary antibody and then with peroxidase-linked secondary antibody according to the manufacturer's protocol. The Amersham ECL chemiluminescence system (GE Healthcare Life Science) was used to detect the peroxidase activity of the bound antibody. In experiments with replication-deficient adenoviral vector, cells were infected with Ad-HER2-ECD or Ad-GFP at a multiplicity of infection (MOI) of 50 for 48 h.
Flowcytometric analysis
To measure the expression of HER2-ECD in cells infected with Ad-HER2-ECD, cells were labeled with APC-conjugated mouse monoclonal anti-HER2-ECD antibody (R&D Systems Inc.) or APC-conjugated IgG2b as control (Miltenyi Biotec, Inc.) on ice for 45 min and were then analyzed using a FACS instrument (BD Biosciences). The intensity of staining was determined using the BD-FACS Software (Flow Jo 7.6.1).
Immunocytochemistry
Cells cultured on 4 chamber glass slides were fixed with 4 % paraformaldehyde in PBS for 15 min and blocked with 3 % bovine serum albumin for 30 min. Slides were then labeled with APC-conjugated mouse monoclonal anti-HER2-ECD antibody (R&D Systems Inc.) on ice for 45 min and were subsequently photographed using a Confocal Laser Scanning Biological Microscope with a 647-nm excitation filter (FV10i, Olympus, Tokyo, Japan).
Synthesis of IR700-conjugated trastuzumab
Trastuzumab was obtained from Chugai Pharmaceutical Co. The IR700 dye (LI-COR Biosciences) was conjugated to trastuzumab following the manufacturer's instructions. Briefly, trastuzumab (1 mg) was incubated with IR700 (66.8 mg, 34.2 nmol, 5 mmol/L in DMSO) in 0.1 mol/L Na 2 HPO 4 (pH 8.6) at room temperature for 1 h. Conjugated Tra-IR700 was purified using a Sephadex G50 column (PD-10; GE Healthcare). Protein concentrations were determined using a Coomassie Plus Protein Assay Kit (Pierce Biotechnology) by measurement of light absorption at 620 nm (8453 Value System; Agilent Technologies).
Fluorescence microscopy
To detect specific antigen-mediated localization of IR700 on the surface of MCF7 and MDA-MB-231 cells, the cells were seeded at 2 9 10 4 /well on cover glass-bottomed dishes, incubated for 24 h, and infected with Ad-HER2-ECD at an MOI of 50 for 48 h. Tra-IR700 (10 lg/ml) was then added to the culture medium and incubated for 6 h at 37°C. The cells were washed with PBS and fluorescence was observed under a Confocal Laser Scanning Biological Microscope (FV10i, Olympus, Japan) with a 647-nm excitation filter.
In vitro Photoimmunotherapy
Cells were seeded on 35 mm cell-culture dishes at 2 9 10 4 /well or 96-well black plates at 5 9 10 3 /well, and were infected with Ad-HER2-ECD or Ad-GFP at an MOI of 50 for 48 h. The medium was then replaced with fresh culture medium containing 10 lg/ml of Tra-IR700 and was further incubated for 6 h at 37°C. After washing with PBS, the cells were then irradiated with light from a red lightemitting diode at wavelengths of 670-690 nm for 35 mm cell-culture dishes and at a wavelength of 625 nm for 96-well black plates. The filter set to detect IR700 when observed under a fluorescence microscope (IX71; Olympus, Tokyo, Japan) consisted of a 590-650-nm excitation filter and a 665-740-nm band pass emission filter. Power density ranged from 40 to 100 mW/cm 2 , as measured using an optical power meter (PM 100, Thorlabs, Inc.).
Cell viability assay
Cell viability was determined 3 days after PIT using the Cell Proliferation Kit II (Roche Molecular Biochemicals) with the sodium 3 0 -[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate (XTT) assay, according to the manufacturer's protocol. Propidium iodide (PI), which is plasma membrane impermeable, was used to stain membrane-disrupted dead cells [11] . PI was added to the medium at an approximate final concentration of 1 lg/mL and was incubated at 37°C for 30 min.
Statistical analysis
A comparison of continuous variables between two groups for in vitro assays was performed using the two-sided Student's t test. Differences between groups were considered to be statistically significant when the p values were \0.05.
Results
HER2-ECD expression induced by Ad-HER2-ECD
MCF7 and MDA-MB-231 breast cancer cells were chosen as HER2 negative breast cancer lines since their expression of HER2 is known to be almost negative, or barely detectable [12] . Initially, Ad-GFP was used as a substitute for Ad-HER2-ECD in preliminary experiments aimed at finding the optimal dose of Ad-HER2-ECD to transduce HER2-ECD into these cells and at examining the transduction efficiency of the adenovirus. We found that an MOI of 50 was the optimal MOI, at which almost all cells were transduced with GFP proteins without cellular toxicity ( Supplementary Fig. 1 ). Based on these data, HER2-negative breast cancer cells were infected with Ad-HER2-ECD at an MOI of 50 for 48 h, to transduce HER2-ECD.
Western blot analysis showed that Ad-HER2-ECD infection resulted in a marked increase in the expression of the 100-kDa HER2-ECD protein in HER2 low-expressing MCF7 and MDA-MB-231 breast cancer cells as compared to parental cells and Ad-GFP-infected cells (Fig. 1a) . Flowcytometric analysis further demonstrated the expression of HER2-ECD on the cell surface (Fig. 1b) . The cell surface expression of HER2-ECD in Ad-HER2-ECDinfected cells was also confirmed using immunocytochemistry (Fig. 1c) .
Trastzumab-IR700 binds to the transduced HER2-ECD We next examined whether Tra-IR700 bound to the HER2-ECD that was overexpressed on MCF7 and MDA-MB-231 cells by Ad-HER2-ECD transduction. Because IR700 is fluorescent, it can be directly detected by fluorescence microscopy allowing visualization of the cellular location of bound Tra-IR700 conjugates. MCF7 and MDA-MB-231 cells were transduced with HER2-ECD using Ad-HER2-ECD and the cells were then incubated with Tra-IR700 for 6 h. Fluorescent imaging confirmed that Tra-IR700 primarily bound to the cell surface of infected, HER2-ECDtransduced cells (Fig. 2) . preceded total cell shrinkage. In MDA-MB-231 cells in contrast, instead of bubbling, many granules appeared in the cytoplasm, followed by shrinkage of the cells (Fig. 3a) . Of note, these changes were observed within 1 min after irradiation with NIR light. A higher amount of light (18 J) resulted in more exaggerated changes in morphology than a lower amount of light (6 J) (Fig. 3a) . Ad-HER2-ECD-infected cells died within 72 h after Tra-IR700 with PIT (6 J), while untreated cells and Ad-GFPinfected cells survived (Fig. 3b) . These phenomena were captured as time-lapse movies (Supplementary movies 1,  2) . We further confirmed cell death of the MCF7 and MDA-MD-231 cells at 72 h after irradiation with NIR light (18 J) by staining of cells whose membranes had been destroyed using PI staining (Fig. 3c) . Morphological change and PI staining of cells immediately following PIT were also reproduced in Ad-HER2-ECD-infected and PIT-treated HER2 negative osteosarcoma Saos-2 cells ( Supplementary Fig. 2 ).
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Phase contrast Tra-IR700 Quantitative evaluation of the cytotoxicity of Trastuzumab-IR700 with PIT for Ad-HER2-ECDinfected HER2 negative cells
The specific cytotoxicity of anti-HER2 PIT was quantitatively evaluated using the XTT assay of cell viability and HER2-transduced MCF7 and MDA-MB-231 cells (Fig. 4a,  b) . Treatment included seven control conditions in addition to Ad-HER2-ECD plus PIT. Only under the treatment condition that employed Ad-HER2-ECD together with Tra-IR700 mediated PIT (24 J for MDA-MB-231 and 36J for MCF-7), cell proliferation was significantly suppressed. In contrast, no significant cytotoxicity was observed under any other condition. Ad-HER2-ECD, Tra-IR700, or NIR irradiation did not harm the cells when each modality was given alone. HER2-specific cytotoxicity of Tra-IR700-mediated PIT was also reproduced in the HER2-positive breast cancer cell, SK-BR-3, and in Ad-HER2-ECDinfected Saos-2 cells ( Supplementary Fig. 3a, b) . These results indicated that Tra-IR700-mediated PIT selectively and specifically targets HER2-ECD-transduced cancer cells.
Discussion
Over the past decades, research has transformed the care of patients with breast cancer through the application of basic science to the clinic [13] . Monoclonal antibodies currently occupy a key position among anti-cancer drugs due to their high specificity and efficacy, which can be achieved in spite of their low side effects. The typical clinical approach for HER2-positive breast cancer has been altered since the approval of trastuzumab [13] . However, for such molecular-targeted therapy, the indication is limited to the populations which express the specific target antigen. In order to overcome this issue, we tried to artificially express the target antigen in target-negative cancer cells by viral transfection. We proved that viral transduction of HER2-ECD made even HER2-negative breast cancer cells sensitive to anti-HER2 photoimmunotherapy. Thus, this technique could expand the indication of antibody-directed therapy to not only target-positive but also to target-negative cancers.
In the present study, we have reproducibly expressed HER2-ECD on the cell membrane of HER2-negative MCF7 and MDA-MB-231 cells, as evidenced by immunocytochemistry as well as by flow cytometry. Although flow cytometric analysis suggested that both parental MCF7 and MDA-MB-231 cells express HER2, the 185 kDa HER2 protein could not be detected in these parental cells by Western blot analysis. These results are consistent with previous reports by other groups, which demonstrated that the levels of HER2 expression in these cell lines are low or negligible and that these cell lines are not sensitive to anti-HER2 therapy [14] [15] [16] .
In addition to confirmation of HER2-ECD expression, we also confirmed that Tra-IR700 bound directly to transduced HER2-ECD by observation under a confocal fluorescence microscope. Since IR700 itself emits fluorescence [17] (Fig. 2) , Tra-IR700 proved to be a useful agent not only for treatment, but also for monitoring [17] [18] [19] . In 
Cell Viability Fig. 4 Effect of Tra-IR700 mediated PIT treatment of HER2-ECD transduced HER2-negative cells on cell viability. Tra-IR700-mediated PIT was applied to the indicated cells along with seven control conditions and cell viability was quantified 72 h after PIT (24 J for MDA-MB-231 and 36 J for MCF-7) using the XTT assay. Only the group of Ad-HER2-ECD-infected cells treated with Tra-IR700-mediated PIT showed target-specific cell death. (n = 4, *p \ 0.05 for Tra-IR700-mediated PIT treatment compared to control groups using Student's t test.)
our previous study, we demonstrated that antibody-dependent cellular cytotoxicity (ADCC) activity against HER2-negative cells or HER2-downregulated cells could be recovered by forced expression of HER2-ECD using Ad-HER2-ECD. At the same time, we confirmed that the expressed HER2-ECD did not activate the HER2 signal transduction pathway and not induce malignant transformation due to the lack of an intracellular kinase domain [9] . There are two main mechanisms by which Trastuzumab stops abnormal cell proliferation; one is through ADCC activity and the other is by blocking signal transduction pathways [20, 21] . However, trastuzumab resistance is known to occur. The cause of trastuzumab resistance appears to be multifactorial [5] . Thus, multimodal treatment strategies are theoretically needed. Indeed, trastuzumab has been mainly used together with chemotherapy or with another monoclonal antibody [6, 7] . However, patients may ultimately suffer from the side effects of coadministered drugs [6, 7] .
Cytotoxic agent-conjugated trastuzumab has been investigated to potentiate the anti-tumor activity of trastuzumab and to exploit the specific overexpression of HER2 on cancer cells [22] [23] [24] . One such agent is Tra-IR700, which was designed to induce cell death only when it is bound to the target cells and when the cells are exposed to NIR [8] . Although the mechanism of cell death induced by PIT remains to be fully elucidated, it assumed to differ from that in conventional photodynamic therapy or in antibody-mediated cytotoxicity [8, 25] . The mode of cytotoxicity in HER2-ECD-targeted Tra-IR700-mediated PIT is also different from ADCC activity or from a block in signal transduction pathways. In the present study, the cytotoxic effect of Ad-HER2-ECD plus Tra-IR700 with PIT was clearly shown by cellular morphological changes and by quantitative analysis of cell viability (Figs. 3, 4) . Captured images of morphological change demonstrated that cell membrane injury occurred immediately after PIT, and time-lapse movies allowed continuous observation of morphological change (Supplemental movie 1, 2). Tra-IR700-mediated PIT directly affects the target cellular membrane and quickly damages it, suggesting that PIT for HER2-ECD can lead to target cell death regardless of intracellular conditions. This mechanism of cell death would suggest that this approach would overcome all modes of resistance known in HER2-targeted therapy including those mediated by altered signaling from receptor tyrosine kinases, constitutive phosphoinositide 3-kinase signaling, PIC3CA gene mutations, and amplification of signaling by HER family receptors [5, 26, 27] .
Cell death was induced only in breast cancer cells infected with Ad-HER2-ECD and treated by Tra-IR700 with PIT. In contrast, none of the other incomplete treatment conditions could induce cell death. Thus, targetspecificity was proved to be very high. Furthermore, we also reproduced this effect in HER2 negative, SaOS2 osteosarcoma cells, highlighting the possibility that this approach could be applied to cells irrespective of the tissue of origin, as long as the adenovirus can infect the target cell.
Although targeting a forcibly-transduced target seems to be an attractive approach, this approach might not be applicable to every anti-HER2 targeted therapy. Prior to employment of anti-HER2 PIT, we had exploited the trastuzumab-Saporin (Hum-ZAP: ADVANCED TAR-GETING SYSTEMS, San Diego, USA) conjugate, the socalled ''immunotoxin''. However, that strategy was unsuccessful, probably because of a defect in trans-membrane internalization of HER2-ECD (data not shown). Thus, any toxins or cytotoxic drugs such as Trastuzumab-DM1 [16, 28, 29] , which require intracellular uptake to exert their toxicity, may not be suitable for anti-HER2-ECD-targeted therapy. In contrast, IR700 does not require intracellular trafficking because it can exhibit photo-toxicity at the surface of the membrane. This advantage of IR700 is therefore one of the reasons for the success of PIT in combination with ant-HER2-ECD-targeted therapy.
Since PIT necessitates sufficient NIR irradiation to kill the cancer cells, the actual target lesion must be within the reach of NIR. NIR light has been shown to travel at least several centimeters through human tissues [30] . Clinical potential of this therapy is therefore assumed for superficial cancer such as in a neoadjuvant setting for primary breast cancer, recurrences in the chest wall, and metastatic lesion in the skin from breast cancer. As long as the device that emits NIR light can gain access to the cancer, even an intravisceral approach though an endoscope might be possible [31] . Sano et al. recently reported that PIT enhanced local vascular permeability, which may enhance drug delivery through the so-called ''enhanced permeability and retention'' effect [32] . It is also expected that PIT might improve the efficacy of conventional chemotherapy. Furthermore, intrinsic ADCC activity can be expected simultaneously with PIT.
Next step will be proof of concept studies using HER2-negative breast tumors in mice. When this strategy is applied to a solid tumor model, success also depends on the penetration of adenoviral infection into tumor besides the reach of NIR light. Since Ad-HER2-ECD is a non-replicating adenoviral vector, intratumoral transduction might show at the less than ideal level [33] . Thus far, more appropriate viral and no-viral gene delivery systems have been extensively developed to be applied to preclinical and clinical studies [34, 35] . Therefore, in case of the application to in vivo study, the optimal vector such as a tumor-specific replicating adenovirus [36] might be preferred to deliver the gene of the target antigen.
In conclusion, we demonstrated that the combination therapy of Ad-HER2-ECD and Tra-IR700 with PIT effectively and selectively killed HER2-negative cells in vitro. This result suggests that viral transduction technology will enable expansion of the indication of antibody-based therapy even to the target-negative group. Therefore, this strategy may also be applicable to other therapeutic antibodies that are currently being developed in rapid succession. The novel combination of gene transfer technology and antibody-based photoimmunotherapy is a promising approach for breaking the limitations of, and resistance to, cancer therapy.
